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Background: Human breast cancer resistance protein (BCRP) is an ATP-binding cassette (ABC) efflux transporter
that confers multidrug resistance in cancers and also plays an important role in the absorption, distribution and
elimination of drugs. Prediction as to if drugs or new molecular entities are BCRP substrates should afford a cost-
effective means that can help evaluate the pharmacokinetic properties, efficacy, and safety of these drugs or drug
candidates. At present, limited studies have been done to develop in silico prediction models for BCRP substrates.
In this study, we developed support vector machine (SVM) models to predict wild-type BCRP substrates based on a
total of 263 known BCRP substrates and non-substrates collected from literature. The final SVM model was
integrated to a free web server.
Results: We showed that the final SVM model had an overall prediction accuracy of ~73% for an independent
external validation data set of 40 compounds. The prediction accuracy for wild-type BCRP substrates was ~76%,
which is higher than that for non-substrates. The free web server (http://bcrp.althotas.com) allows the users to
predict whether a query compound is a wild-type BCRP substrate and calculate its physicochemical properties such
as molecular weight, logP value, and polarizability.
Conclusions: We have developed an SVM prediction model for wild-type BCRP substrates based on a relatively
large number of known wild-type BCRP substrates and non-substrates. This model may prove valuable for
screening substrates and non-substrates of BCRP, a clinically important ABC efflux drug transporter.
Keywords: Breast cancer resistance protein, Support vector machine, SVM, ATP-binding cassette, ABC transporter,
in silico prediction, Substrate, BCRP, ABCG2Background
Human breast cancer resistance protein (BCRP, gene
symbol ABCG2) is an ATP-binding cassette (ABC) efflux
drug transporter [1,2]. BCRP is one of the ABC trans-
porters that confer resistance to a large number of struc-
turally and chemically unrelated chemotherapeutic agents
through ATP hydrolysis-dependent efflux transport of
these drugs [2]. The substrates of BCRP have been rapidly
expanding to include not only chemotherapeutics such as
mitoxantrone, topotecan and imatinib, but also non-
chemotherapeutic drugs such as prazosin, glyburide,
nitrofurantoin and statins as well as non-therapeutic* Correspondence: qmao@u.washington.edu
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reproduction in any medium, provided the orcompounds such as dietary flavonoids, porphyrins, estrone
3-sulfate, and the dietary carcinogen 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine [1,2]. BCRP is also highly
expressed in organs important for the absorption (the
small intestine), elimination (the liver and kidney), and
distribution (the blood–brain and placental barriers) of
drugs and xenobiotics [3], and has recently been recog-
nized by the FDA as one of the most important drug
transporters involved in clinically relevant drug dispos-
ition and drug-drug interactions [4]. Due to the clinical
importance of BCRP in drug resistance and drug dispos-
ition, it should be of high value to develop cost-effective
methods for evaluation of transport of drugs or drug can-
didates by BCRP so that the pharmacokinetics, efficacy,
safety, and tissue levels of these compounds may betd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ment of in silico models for prediction of BCRP
substrates.
Indeed, in the recent years, in silico prediction models
have emerged into the pipeline of drug discovery which
allow initial screening and selection of promising com-
pounds from chemical libraries and large databases. In
addition, these models could provide information
concerning the mechanism of protein-ligand interac-
tions. In silico methods for prediction of protein-ligand
interactions including transport characteristics can be
divided into ligand-based and protein structure-based
approaches. With protein structure-based methods such
as molecular docking, structures and physicochemical
characteristics of an intermolecular complex formed be-
tween interacting protein and ligand could be predicted
if high resolution structures of both the protein and the
ligand under question are available. High resolution
structures of BCRP have not been resolved. Homology
models of BCRP have recently been developed and await
further experimental validation [1,5]. Although these
homology models can be used for docking calculations
and interpretation of biochemical data, results obtained
are unlikely reliable for drug design and screening. In con-
trast, ligand-based methods based on structural similarity
of ligands to known substrates generally yield much
greater prediction accuracies than protein structure-based
methods.
Among ligand-based methods, one common approach
is to develop quantitative structure-activity relationship
models (SAR and QSAR). The objective of SAR and
QSAR analysis is to establish a correlation between de-
scriptors which represent information of molecular
structures of ligands and biological activities for a series
of biologically and structurally characterized com-
pounds. Various SAR and QSAR models for BCRP
inhibitors have been published [6-8]. Several SAR and
QSAR studies suggest that lipophilicity of ligands is a
good predictor for BCRP inhibition [9-11], but other
studies argue that this property is not significant [12,13].
A planar structure of inhibitors seems to be necessary
for binding to the active site of BCRP [9,14,15]. With
respect to prediction of BCRP substrates, only one SAR
study of camptothecin analogues revealed that hydrogen
bond formation might be important for substrate recog-
nition by BCRP [16]. One common feature of these SAR
and QSAR models is that these models are usually built
using a congeneric series of molecules and thus may not
be valid for other classes of compounds. For this reason,
more sophisticated techniques are required for classifica-
tion of BCRP ligands.
Another ligand-based approach is to use statistical
learning methods to predict features based on properties
of examples, and compounds of any chemical structurescan be used. Of these methods, the support vector
machine (SVM) method is most frequently used and has
proved valuable in a wide range of applications. SVM
has gained popularity in the chemo- and bioinformatics
field due to its ability to classify objects into two classes
based on their structural features. In particular, the SVM
method was useful for classification of molecules as sub-
strates or non-substrates of enzymes or transporters. For
example, several studies have been reported for predic-
tion of substrates and non-substrates of P-glycoprotein
(P-gp) using SVM with generally greater than 70% pre-
diction accuracies [17-20]. Zhong et al. recently reported
a genetic algorithm-conjugate gradient-support vector
machine (GA-CG-SVM) procedure for prediction of
BCRP substrates and non-substrates [21]. Although
these studies are highly valuable, the scientific commu-
nity has no open access to most of these published in
silico models. There are a few SVM-based free web
servers for predicting substrates and non-substrates of
certain enzymes and transporters. For example, Mishra
et al. reported a web server for cytochrome P450
enzymes [22], and our laboratories published a free web
server for prediction of P-gp substrates and non-
substrates using the SVM method (http://pgp.althotas.
com) [20].
Therefore, in the present study, we have compiled a
relatively large data set of BCRP substrates and non-
substrates collected from literature and developed an
SVM-based in silico model for prediction of wild-type
BCRP substrates and non-substrates. This prediction
model has been integrated into a free web server (http://
bcrp.althotas.com) which allows the users to predict the
capability of wild-type BCRP to transport the query
ligands and calculate their physiochemical properties in-
cluding molecular weight, logP value, and polarizability.
Methods
Data set
All known wild-type BCRP substrates and non-
substrates used in this study were taken from published
data in the literature. Information for some of these
compounds in the data set was obtained through
searching the University of Washington Metabolism &
Transport Drug Interaction Database (http://www.
druginteractioninfo.org/). This data set is based on re-
sults of in vitro transport assays such as the membrane
vesicle uptake assay, the efflux assay using intact mam-
malian cells over-expressing BCRP, and transwell trans-
port assay using MDCKII/BCRP cells. Results from
in vitro drug resistance assays were also used. However,
results from drug-stimulated ATPase assays were not
used because many substrates do not stimulate ATPase
activity of BCRP. In the case of conflicting evidence,
only the results confirmed by at least two independent
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substrates and 99 non-substrates with highly diverse
chemical structures. We noticed that 60 out of the 164
substrates had multiple reports. However, only about 9
out of the 99 non-substrates had multiple reports. It is
worth noting that the drug-selected BCRP mutants with
amino acid substitutions at position 482 exhibit altered
substrate specificity. For example, doxorubicin, rhoda-
mine 123 and LysoTracker Green are substrates of the
mutant R482G or R482T, but cannot be efficiently
transported by wild-type BCRP [23-25]. Therefore, such
compounds were classified as non-substrates of wild-
type BCRP which was the subject of this study. Of the
263 compounds (164 substrates and 99 non-substrates),
223 compounds (139 substrates and 84 non-substrates)
were randomly used in the training and test subsets in
various training/test ratios, and 40 compounds (25 sub-
strates and 15 non-substrates) were defined as the inde-
pendent external validation subset. All compounds are
listed in Additional file 1: Table S1. The chemical struc-
tures of all these molecules are shown in two sdf files
provided as Additional files 2 and 3 which can be viewed
using the free MarvinView software (http://www.
chemaxon.com/products/marvin/marvinview/).
Support vector machine (SVM)
The SVM method we used in this study is essentially the
same as previously described [20]. Briefly, the standard
procedure of classification by SVM can be divided into
four stages. In the first stage, all compounds in the data
set were defined as substrates and non-substrates of
wild-type BCRP. Then, the molecules were characterized
using molecular descriptors. The data set was then split
into the training and test subsets, and an independent
external validation subset was also created. In the second
stage, the compounds in the training set were presented
as points in a high-dimensional space according to their
molecular descriptors. In this high-dimensional space, a
hyperplane was determined to separate objects into sub-
strate and non-substrate groups. Since various hyper-
planes allow separation of objects, a hyperplane that
maximizes the margin needs to be constructed. In the
third stage, the models constructed using the training
data set were used to calculate prediction accuracy for a
test set to evaluate the models. Finally, the models were
validated using the independent external data set.
Chemical structures of all wild-type BCRP substrates
or non-substrates used in this study were downloaded
from the PubChem Database (http://pubchem.ncbi.nlm.
nih.gov). Some compounds were extracted from the ori-
ginal publications and redrawn by means of MarvinView
(ChemAxon, Budapest, Hungary). All molecules were
subject to geometry optimization using the Molconvert
software (ChemAxon, Budapest, Hungary), which appliesthe Dreiding molecular mechanics force field, and to cal-
culation of the Gasteiger partial charges [26]. The
DragonX software (www.talete.mi.it) was used to calcu-
late a total of 3250 molecular descriptors for each mol-
ecule. The descriptors with more than 80% zero values
and too small standard deviation values (less than 3%)
were eliminated. The Libsvm software (www.csie.ntu.
edu.tw/~cjlin/libsvm/) was then used for SVM calcula-
tions. Linear, polynomial, and radial basis function (RBF)
kernels were tested in this study. RBF is calculated using
the equation K(xi, xj) = exp(−γ||xi-xj||2), where γ is a
kernel parameter, xi and xj are instance label pairs, and
K is the kernel function. The prediction power of SVM
is greatly influenced by the selection of kernel, the kernel
parameter γ, and soft margin parameter C.
The best combination of C and γ was selected by a
grid-search with exponentially growing sequences of C
and γ. Each combination of parameter choices was
checked, and the parameters with the best validation
accuracy were selected. After the best parameters C and
γ were found, the whole training set was trained again to
generate the final model. The feature selection tool
fselect.py (http://www.csie.ntu.edu.tw/~cjlin/libsvmtools)
provided by the Libsvm developer was used to measure
the relative importance of each feature. For each feature,
an F-score can be calculated using fselect.py. Generally,
the larger the F-score, the more likely the feature is dis-
criminative. Therefore, F-score was used as a feature
selection criterion. Features with high F-scores were se-
lected and then SVM was applied. High F-score features
were gradually added until the validation accuracy de-
creased. Descriptors were checked for their correlation.
Among the descriptors with a correlation of 0.9, the de-
scriptors with higher F-scores were kept for further
SVM calculations. Prediction power of the above-
described SVM method was evaluated based on the
number of true positive (TP), true negative (TN), false
positive (FP), and false negative (FN) predictions. Add-
itional parameters that are widely used, namely accuracy
(ACC), sensitivity (SE), specificity (SP), and the Matthews
correlation coefficient (MCC), were also calculated using
the following equations:
ACC ¼ TPþ TNð Þ= TPþ TNþ FPþ FNð Þ½   100
SE ¼ TP= TPþ FNð Þ½   100
SP ¼ TN= FPþ TNð Þ½   100
MCC ¼ TP TN FP FNð Þ= TPþ FNð Þ TPþ FPð Þ½
TNþ FPð Þ TNþ FNð Þ1=2
The web server
The best prediction model generated using the SVM
method described above has been integrated into a free
web server (http://bcrp.althotas.com). This web server
allows the users to predict as to whether a query
Table 2 Performance parameters of 100 runs using
various ratios of training/test sets
Training/Test ratio Category ACC SE SP MCC
0.5/0.5 Training 83.8 94.6 65.8 0.649
Test 67.8 82.2 44.0 0.288
External 69.5 78.3 54.7 0.344
0.6/0.4 Training 85.1 94.7 69.1 0.678
Test 69.0 83.2 45.5 0.315
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ical structure of the query compounds can be uploaded
or drawn in by the users using the built-in Chemaxon
Marvin Java applet. The web server is linked to
PubChem so that any query compounds can be directly
retrieved with text search. Any compounds of interest
can be searched by their names, uploaded in PDB, mol,
mol2, hin, or SMILES format or drawn in using a
Marvin applet by the users. Structural conversions and
3-dimensional geometry optimization by the Dreiding
method are carried out using the Molconvert software.
Two-dimensional and 3-dimensional molecular descrip-
tors are calculated using the DragonX software.
Results and discussion
Since SVM tends to find a linear separating hyperplane
with the maximal margin in a high-dimensional space by
using a penalty parameter of the error term and a kernel
function, we first investigated the influence of kernel
function on the performance parameters. SVM predic-
tion performance parameters of 100 runs with different
kernel functions (linear, polynomial, and RBF) are pro-
vided in Table 1. The data shown in Table 1 were
obtained using a training set of 167 compounds, a test
set of 56 compounds, and an external validation set of
40 compounds. The test set was used for choosing the
best kernel function, and test performances were used as
the criteria for selecting the best kernel. It should be em-
phasized that the external validation set was not used in
the model building steps. It appeared that polynomial
kernel function produced generally lower prediction
accuracy compared to linear kernel function and RBF.
Although performance parameters associated with linearTable 1 The mean values of SVM prediction performance
parameters of 100 runs using various kernels
Kernel Category ACC SE SP MCC
Linear Training 80.7 90.4 64.8 0.581
Test 68.8 82.1 46.6 0.312
External 70.7 77.6 59.1 0.375
Polynomial Training 79.2 96.4 50.7 0.506
Test 65.8 86.8 30.8 0.198
External 66.1 81.9 39.8 0.174
RBF Training 84.5 93.8 69.1 0.665
Test 69.7 83.3 47.2 0.332
External 70.9 77.7 59.6 0.382
ACC, accuracy (overall prediction accuracy); SP, specificity (prediction accuracy
for the non-substrates); SE, sensitivity (prediction accuracy for the substrates);
MCC, the Matthews correlation coefficient (a more balanced prediction
parameter than ACC). The external data set was only used to validate the
prediction power of the models constructed, and was not used for
model selection.and RBF kernels were comparable, RBF provided slightly
better prediction results. This is consistent with a gen-
eral practice that RBF is the most popular choice of ker-
nel function in SVM. Based on results of this
preliminary evaluation, only RBF was used in further
calculations.
Due to the limited number of currently known wild-
type BCRP substrates and non-substrates, if more com-
pounds are used in the training set, fewer compounds
can be used in the test set, likely resulting in less reliable
test prediction outcome. Therefore, we next investigated
the influence of the number of compounds in the train-
ing and test sets on prediction accuracy. The results of
SVM calculations performed with varying training/test
set ratios are shown in Table 2. Overall, we did not ob-
serve significant differences in the performance parame-
ters with different training/test ratios. However, the
MCC values at the training/test ratios of 0.75/0.25; 0.70/
0.30 and 0.60/0.40 appeared to be comparable and
slightly better than those at other ratios. Similar to the
kernel selection, only the test and training data sets wereExternal 70.8 79.0 57.1 0.372
0.7/0.3 Training 83.4 93.3 67.1 0.642
Test 71.1 84.2 49.1 0.360
External 70.8 78.4 58.1 0.375
0.75/0.25 Training 84.5 93.8 69.1 0.665
Test 69.7 83.3 47.2 0.332
External 70.9 77.7 59.6 0.382
0.8/0.2 Training 83.6 93.5 67.1 0.644
Test 70.4 83.6 48.7 0.35
External 70.6 77.5 59.1 0.376
0.85/0.15 Training 82.9 93.5 65.1 0.627
Test 70.3 85.1 46.4 0.347
External 70.9 78.5 58.1 0.376
The total number of molecules used in the training and test data sets were
223. The number of molecules in the external validation data set was 40. ACC,
accuracy (overall prediction accuracy); SP, specificity (prediction accuracy for
the non-substrates); SE, sensitivity (prediction accuracy for the substrates);
MCC, the Matthews correlation coefficient (a more balanced prediction
parameter than ACC). The external data set was only used to validate the
prediction power of the models constructed, and was not used for
model selection.
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data set was only used for validation of the models
constructed. Thus, the training/test ratio of 0.75/0.25
was chosen for further calculations in order to maximize
the chemical space occupied by the molecules in the
training set.
There is no general rule regarding selection of the best
SVM prediction model. The run that provides the
highest prediction accuracy for the training set may be
selected. However, such an approach could be mislead-
ing because a model with the highest prediction accur-
acy (or Matthews correlation coefficient) for a training
set does not necessarily produce the highest prediction
accuracy (or Matthews correlation coefficient) neither
for the test set nor for the independent external valid-
ation set due to a phenomenon called overfitting. It is
therefore necessary to consider prediction characteristics
of both the training and test sets when the best SVM
model is to be selected. In our study for prediction of P-
gp substrates [20], we proposed the following approach.
First, the differences in prediction accuracy between the
training and test sets were calculated, and the models
with the smallest difference were taken into account.
Second, of the models with the smallest difference in
prediction accuracy between the training and test sets,
those built with the smallest number of molecular de-
scriptors were considered because inclusion of too many
descriptors may again produce overfitted models and the
inclusion of unnecessary or irrelevant descriptors creates
noise in the model. We showed that classification of
individual compounds in the independent external valid-
ation set as substrates or non-substrates of P-gp was
very similar among the potentially best models [20].
Using the same approach, the best SVM prediction
model was selected for substrates of wild-type BCRP
and the prediction performance parameters of the
selected model are shown in Table 3. The selected model
showed an overall prediction accuracy of ~73% for the
external validation data set. Also, wild-type BCRP sub-
strates were generally predicted with a higher accuracy
than non-substrates (Table 3). In the SVM prediction,Table 3 Prediction power of the selected SVM model
TP FN TN FP ACC SE SP MCC
Training set 89 15 38 25 76.0 85.6 60.3 0.478
Test set 31 4 11 10 75.0 88.6 52.4 0.448
External set 19 6 10 5 72.5 76.0 66.7 0.422
TP, true positive; TN, true negative; FP, false positive; FN, false negative; ACC,
accuracy (overall prediction accuracy); SP, specificity (prediction accuracy for
the non-substrates); SE, sensitivity (prediction accuracy for the substrates);
MCC, the Matthews correlation coefficient (a more balanced prediction
parameter than ACC).there is generally a borderline region where the struc-
tural properties of substrates and non-substrates are very
similar, and therefore compounds in this borderline
region cannot be separated by their structural properties
alone. In our model, molecules in this borderline region
were mainly predicted as substrates. This may contribute
to the higher prediction accuracy for substrates.
Classification of individual compounds as wild-type
BCRP substrates or non-substrates was very similar
among the 10 selected models in the first step. Table 4
shows the overlap in classification (i.e. the percentage of
compounds that were identically predicted by the com-
pared models) among these 10 models. As can be seen
in Table 4, classification of compounds to be wild-type
BCRP substrates or non-substrates in different models
were highly similar, that is, the overlap values varied be-
tween 81.4% and 94.3%, with an average of 88.5%. For
example, 85.93% of compounds were predicted to be in
the same category (substrates or non-substrates) by the
model 87 compared to the model 63, which has the
highest prediction accuracy. This finding suggests that,
to obtain reliable predictions, selection of the best model
is likely not as important as, for example, the compil-
ation of high quality data sets. In this regard, we would
like to point out that the data set collected in this study
regarding whether a specific compound is a substrate of
wild-type BCRP could be obtained using different trans-
port methods. This does not affect the prediction accur-
acy of our model as long as the different transport
methods produce the same result as to if the compound
is a BCRP substrate. This is because the SVM model
only makes qualitative (substrates or non-substrates),
not quantitative (e.g., transport capacity) prediction.
Recently, an SVM study based on a different data set was
published by Zhong et al. [21] and reported a higher over-
all prediction accuracy for BCRP substrates and non-
substrates (85% for the test set). It should be noted that the
compounds used by Zhong et al. were only divided into
two sets, namely a training set and a test set, without an in-
dependent external validation data set. Also, the test set
used by Zhong et al. was not independent when it was
used for the selection of the best model. Therefore, their
results cannot be directly compared to the data of this
study. This is because, besides the training and test sets,
we also used an independent external validation data set to
evaluate prediction outcome and calculate prediction ac-
curacies of the selected best model. Moreover, certain com-
pounds in the data sets of Zhong et al. were actually the
same under different names (e.g., folic acid versus vitamin
B9 and daunomycin versus daunorubicin). Additionally, a
number of compounds were classified as BCRP substrates
(e.g., daunorubicin, rhodamine 123, LysoTracker Green,
and epirubicin) by Zhong et al., but as non-substrates in
this study as explained in the Methods section.
Table 4 Overlap of classification in 10 experimental models
Experimental model 98 87 77 63 91 45 42 62 7 73
98 100 86.31 87.07 86.69 84.41 81.37 87.07 87.07 87.45 86.69
87 100 87.83 85.93 87.45 81.37 87.83 87.07 87.45 90.49
77 100 89.73 94.30 87.45 91.64 92.34 89.73 91.26
63 100 87.83 84.79 88.21 89.73 89.35 88.59
91 100 88.59 88.97 94.30 91.64 92.40
45 100 85.93 88.21 84.79 84.79
42 100 91.64 92.78 92.02
62 100 91.26 91.26
7 100 91.26
73 100
The overall prediction accuracies (ACC) of the 10 experimental models 98, 87, 77, 63, 91, 45, 42, 62, 7, and 73 were 78.33%, 75.29%, 76.81%, 80.23%, 75.67%,
70.34%, 76.05%, 75.29%, 78.71%, and 77.95%, respectively.
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used the molecular descriptors shown in Table 5. That is,
the following descriptors were found to be used in the final
model: mean information index on atomic composition
(AAC), spherosity (SPH), Morse signals, and a mass
weighed Gateway descriptor. These descriptors suggest that
the 3-dimensional structure of a substrate is likely the de-
termining factor for BCRP/substrate interactions. The re-
sults of classification by this SVM model for all compounds
used in this study are shown in Additional file 1: Table S1.
In order to make the SVM model publicly available,
we developed a free web server (http://bcrp.althotas.
com). This web server enables the users to predict if a
query compound is a BCRP substrate based on the se-
lected SVM prediction model of this study.
Conclusions
In summary, BCRP is an ABC drug transporter that con-
fers multidrug resistance in cancers and plays an import-
ant role in drug disposition. Therefore, it is important to
develop in silico prediction models for BCRP substrates
that could be used as cost-effective tools for screening ofTable 5 List of molecular descriptors found to be used by




AAC Mean information index on atomic composition
SPH spherosity
Mor17m 3D Morse signal 17/weighed by mass
Mor25m 3D Morse signal 25/weighed by mass
R2m Gateway R autocorrelation of lag2 weighed by
massdrug candidates in early drug discovery stage and for
identification of BCRP substrates among existing drugs
so that potential drug-drug interactions may be pre-
dicted. In the present study, using a carefully defined
and relatively large data set with 263 known wild-type
BCRP substrates and non-substrates, we have developed
an SVM model for prediction of wild-type BCRP sub-
strates and non-substrates with an overall prediction
accuracy of ~73% for an independent external validation
data set of 40 compounds. The prediction accuracy for
wild-type BCRP substrates was ~76%, which is higher
than that for non-substrates. The molecular descriptors
used by this SVM model suggest that the 3-dimensional
structure of a compound is possibly a predominant fac-
tor in determining BCRP/substrate interactions. This
SVM prediction model has been integrated into a web
server (http://bcrp.althotas.com) which is freely available
to the scientific community. We believe that availability
of such a prediction model will facilitate drug discovery
as well as basic research investigating the role of BCRP
in drug transport.
Additional files
Additional file 1: All the wild-type BCRP substrates and non-
substrates used in this study and classification of these compounds
by the selected SVM prediction model developed in this study are
shown in the supplemental Table S1.
Additional file 2: The chemical structures of all wild-type BCRP
substrates are shown in this sdf file which can be viewed using the
free MarvinView software (http://www.chemaxon.com/products/
marvin/marvinview/). The order of molecules in the sdf file is according
to the supplementary Table S1.
Additional file 3: The chemical structures of all wild-type BCRP
non-substrates are shown in this sdf file which can be viewed using
the free MarvinView software (http://www.chemaxon.com/products/
marvin/marvinview/). The order of molecules in the sdf file is according
to the supplementary Table S1.
Hazai et al. BMC Bioinformatics 2013, 14:130 Page 7 of 7
http://www.biomedcentral.com/1471-2105/14/130Abbreviations
ABC: ATP-binding cassette; BCRP: Breast cancer resistance protein;
ABCG2: The second member of ABC transporter subfamily G; SVM: Support
vector machine; ACC: Accuracy (overall prediction accuracy); SP: Specificity
(prediction accuracy for non-substrates); SE: Sensitivity (prediction accuracy
for substrates); MCC: Matthews correlation coefficient (a more balanced
prediction parameter than ACC); SD: Standard deviation; TP: True positive;
FP: False positive; TN: True negative; FN: False negative.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EH: data analysis and interpretation, manuscript preparation, and final
approval of the version to be published; IH: collection of data sets, data
analysis and interpretation, manuscript preparation; SC: collection of data
sets and critical revision of the manuscript; IR-M: collection of data sets and
critical revision of the manuscript; ZB: data analysis and interpretation,
manuscript preparation, and final approval of the version to be published;
QM: collection of data sets, data analysis and interpretation, manuscript
preparation, and final approval of the version to be published. All authors
read and approved the final manuscript.
Acknowledgements
This work was supported by the Hungarian State and the European Union
(European Regional Development Fund), under the aegis of New Hungary
Development Plan (KMOP-1.1.1-09/1-2009-0044), and by a grant from the
National Institutes of Health, GM073715 (to QM).
Author details
1Virtua Drug Ltd., Csalogany Street 4, Budapest H-1015, Hungary.
2Department of Pharmaceutics, School of Pharmacy, University of
Washington, Box 357610, Seattle, Washington 98195, USA.
Received: 6 November 2012 Accepted: 12 April 2013
Published: 15 April 2013
References
1. Ni Z, Bikadi Z, Rosenberg MF, Mao Q: Structure and function of the
human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab
2010, 11(7):603–617.
2. Natarajan K, Xie Y, Baer MR, Ross DD: Role of breast cancer resistance
protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol
2012, 83(8):1084–1103.
3. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC,
Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH: Subcellular
localization and distribution of the breast cancer resistance protein
transporter in normal human tissues. Cancer Res 2001, 61(8):3458–3464.
4. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin
A, Evers R, Fischer V, Hillgren KM, et al: Membrane transporters in drug
development. Nat Rev Drug Discov 2010, 9(3):215–236.
5. Rosenberg MF, Bikadi Z, Chan J, Liu X, Ni Z, Cai X, Ford RC, Mao Q: The
human breast cancer resistance protein (BCRP/ABCG2) shows
conformational changes with mitoxantrone. Structure 2010, 18(4):482–493.
6. Gandhi YA, Morris ME: Structure-activity relationships and quantitative
structure-activity relationships for breast cancer resistance protein
(ABCG2). AAPS J 2009, 11(3):541–552.
7. Ishikawa T, Hirano H, Saito H, Sano K, Ikegami Y, Yamaotsu N, Hirono S:
Quantitative structure-activity relationship (QSAR) analysis to predict
drug-drug interactions of ABC transporter ABCG2. Mini Rev Med Chem
2012, 12(6):505–514.
8. Nicolle E, Boumendjel A, Macalou S, Genoux E, Ahmed-Belkacem A, Carrupt
PA, Di Pietro A: QSAR analysis and molecular modeling of ABCG2-specific
inhibitors. Adv Drug Deliv Rev 2009, 61(1):34–46.
9. Zhang S, Yang X, Coburn RA, Morris ME: Structure activity relationships
and quantitative structure activity relationships for the flavonoid-
mediated inhibition of breast cancer resistance protein. Biochem
Pharmacol 2005, 70(4):627–639.
10. van Loevezijn A, Allen JD, Schinkel AH, Koomen GJ: Inhibition of BCRP-
mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.
Bioorg Med Chem Lett 2001, 11(1):29–32.11. Matsson P, Englund G, Ahlin G, Bergstrom CA, Norinder U, Artursson P: A
global drug inhibition pattern for the human ATP-binding cassette
transporter breast cancer resistance protein (ABCG2). J Pharmacol Exp
Ther 2007, 323(1):19–30.
12. Cramer J, Kopp S, Bates SE, Chiba P, Ecker GF: Multispecificity of drug
transporters: probing inhibitor selectivity for the human drug efflux
transporters ABCB1 and ABCG2. ChemMedChem 2007, 2(12):1783–1788.
13. Pick A, Muller H, Wiese M: Structure-activity relationships of new
inhibitors of breast cancer resistance protein (ABCG2). Bioorg Med Chem
2008, 16(17):8224–8236.
14. Ahmed-Belkacem A, Pozza A, Munoz-Martinez F, Bates SE, Castanys S,
Gamarro F, Di Pietro A, Perez-Victoria JM: Flavonoid structure-activity
studies identify 6-prenylchrysin and tectochrysin as potent and specific
inhibitors of breast cancer resistance protein ABCG2. Cancer Res 2005,
65(11):4852–4860.
15. Ahmed-Belkacem A, Macalou S, Borrelli F, Capasso R, Fattorusso E,
Taglialatela-Scafati O, Di Pietro A: Nonprenylated rotenoids, a new class of
potent breast cancer resistance protein inhibitors. J Med Chem 2007,
50(8):1933–1938.
16. Nakagawa H, Saito H, Ikegami Y, Aida-Hyugaji S, Sawada S, Ishikawa T:
Molecular modeling of new camptothecin analogues to circumvent
ABCG2-mediated drug resistance in cancer. Cancer Lett 2006,
234(1):81–89.
17. Wang Z, Chen Y, Liang H, Bender A, Glen RC, Yan A: P-glycoprotein
substrate models using support vector machines based on a
comprehensive data set. J Chem Inf Model 2011, 51(6):1447–1456.
18. Xue Y, Yap CW, Sun LZ, Cao ZW, Wang JF, Chen YZ: Prediction of
P-glycoprotein substrates by a support vector machine approach.
J Chem Inf Comput Sci 2004, 44(4):1497–1505.
19. Huang J, Ma G, Muhammad I, Cheng Y: Identifying P-glycoprotein
substrates using a support vector machine optimized by a particle
swarm. J Chem Inf Model 2007, 47(4):1638–1647.
20. Bikadi Z, Hazai I, Malik D, Jemnitz K, Veres Z, Hari P, Ni Z, Loo TW, Clarke
DM, Hazai E, et al: Predicting P-glycoprotein-mediated drug transport
based on support vector machine and three-dimensional crystal
structure of P-glycoprotein. PLoS One 2011, 6(10):e25815.
21. Zhong L, Ma CY, Zhang H, Yang LJ, Wan HL, Xie QQ, Li LL, Yang SY: A
prediction model of substrates and non-substrates of breast cancer
resistance protein (BCRP) developed by GA-CG-SVM method. Comput Biol
Med 2011, 41(11):1006–1013.
22. Mishra NK, Agarwal S, Raghava GP: Prediction of cytochrome P450 isoform
responsible for metabolizing a drug molecule. BMC Pharmacol 2010, 10:8.
23. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A,
Litman T, Dean M, Bates SE: Acquired mutations in the MXR/BCRP/ABCP
gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
Cancer Res 2001, 61(18):6635–6639.
24. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M,
Poruchynsky MS, Bates SE: Mutations at amino-acid 482 in the ABCG2
gene affect substrate and antagonist specificity. Br J Cancer 2003,
89(10):1971–1978.
25. Ozvegy-Laczka C, Koblos G, Sarkadi B, Varadi A: Single amino acid (482)
variants of the ABCG2 multidrug transporter: major differences in
transport capacity and substrate recognition. Biochim Biophys Acta 2005,
1668(1):53–63.
26. Gasteiger JMM: Iterative partial equalization of orbital electronegativity -
a rapid access to atomic charges. Tetrahedron 1980, 36:3219–3228.
doi:10.1186/1471-2105-14-130
Cite this article as: Hazai et al.: Predicting substrates of the human
breast cancer resistance protein using a support vector machine
method. BMC Bioinformatics 2013 14:130.
